FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3043131535> ?p ?o ?g. }

• W3043131535 endingPage "1143" @default.
• W3043131535 startingPage "1134" @default.
• W3043131535 abstract "Abstract Given advanced age, comorbidities, and immune dysfunction, chronic lymphocytic leukemia (CLL) patients may be at particularly high risk of infection and poor outcomes related to coronavirus disease 2019 (COVID-19). Robust analysis of outcomes for CLL patients, particularly examining effects of baseline characteristics and CLL-directed therapy, is critical to optimally manage CLL patients through this evolving pandemic. CLL patients diagnosed with symptomatic COVID-19 across 43 international centers (n = 198) were included. Hospital admission occurred in 90%. Median age at COVID-19 diagnosis was 70.5 years. Median Cumulative Illness Rating Scale score was 8 (range, 4-32). Thirty-nine percent were treatment naive (“watch and wait”), while 61% had received ≥1 CLL-directed therapy (median, 2; range, 1-8). Ninety patients (45%) were receiving active CLL therapy at COVID-19 diagnosis, most commonly Bruton tyrosine kinase inhibitors (BTKi’s; n = 68/90 [76%]). At a median follow-up of 16 days, the overall case fatality rate was 33%, though 25% remain admitted. Watch-and-wait and treated cohorts had similar rates of admission (89% vs 90%), intensive care unit admission (35% vs 36%), intubation (33% vs 25%), and mortality (37% vs 32%). CLL-directed treatment with BTKi’s at COVID-19 diagnosis did not impact survival (case fatality rate, 34% vs 35%), though the BTKi was held during the COVID-19 course for most patients. These data suggest that the subgroup of CLL patients admitted with COVID-19, regardless of disease phase or treatment status, are at high risk of death. Future epidemiologic studies are needed to assess severe acute respiratory syndrome coronavirus 2 infection risk, these data should be validated independently, and randomized studies of BTKi’s in COVID-19 are needed to provide definitive evidence of benefit." @default.
• W3043131535 created "2020-07-23" @default.
• W3043131535 creator A5000537427 @default.
• W3043131535 creator A5003194414 @default.
• W3043131535 creator A5004152600 @default.
• W3043131535 creator A5007016445 @default.
• W3043131535 creator A5008419917 @default.
• W3043131535 creator A5010100538 @default.
• W3043131535 creator A5010881749 @default.
• W3043131535 creator A5013974745 @default.
• W3043131535 creator A5015896987 @default.
• W3043131535 creator A5016042168 @default.
• W3043131535 creator A5016212100 @default.
• W3043131535 creator A5016570475 @default.
• W3043131535 creator A5016818736 @default.
• W3043131535 creator A5017589040 @default.
• W3043131535 creator A5023426390 @default.
• W3043131535 creator A5023474566 @default.
• W3043131535 creator A5024263110 @default.
• W3043131535 creator A5026821034 @default.
• W3043131535 creator A5026842309 @default.
• W3043131535 creator A5027294123 @default.
• W3043131535 creator A5028299420 @default.
• W3043131535 creator A5028491175 @default.
• W3043131535 creator A5030524385 @default.
• W3043131535 creator A5032020190 @default.
• W3043131535 creator A5032861872 @default.
• W3043131535 creator A5035304428 @default.
• W3043131535 creator A5035890812 @default.
• W3043131535 creator A5035893158 @default.
• W3043131535 creator A5036220283 @default.
• W3043131535 creator A5037565105 @default.
• W3043131535 creator A5037966102 @default.
• W3043131535 creator A5040412322 @default.
• W3043131535 creator A5040703931 @default.
• W3043131535 creator A5041247024 @default.
• W3043131535 creator A5041612097 @default.
• W3043131535 creator A5042184172 @default.
• W3043131535 creator A5042332348 @default.
• W3043131535 creator A5042723532 @default.
• W3043131535 creator A5045820092 @default.
• W3043131535 creator A5047396858 @default.
• W3043131535 creator A5049924304 @default.
• W3043131535 creator A5051296565 @default.
• W3043131535 creator A5052110872 @default.
• W3043131535 creator A5053298824 @default.
• W3043131535 creator A5055100327 @default.
• W3043131535 creator A5060994571 @default.
• W3043131535 creator A5061575461 @default.
• W3043131535 creator A5061964017 @default.
• W3043131535 creator A5062940651 @default.
• W3043131535 creator A5063755644 @default.
• W3043131535 creator A5069318096 @default.
• W3043131535 creator A5070514136 @default.
• W3043131535 creator A5075187236 @default.
• W3043131535 creator A5075537115 @default.
• W3043131535 creator A5077730260 @default.
• W3043131535 creator A5079426839 @default.
• W3043131535 creator A5079663967 @default.
• W3043131535 creator A5080864734 @default.
• W3043131535 creator A5081365965 @default.
• W3043131535 creator A5082541659 @default.
• W3043131535 creator A5083072418 @default.
• W3043131535 creator A5083925677 @default.
• W3043131535 date "2020-09-03" @default.
• W3043131535 modified "2023-10-17" @default.
• W3043131535 title "Outcomes of COVID-19 in patients with CLL: a multicenter international experience" @default.
• W3043131535 cites W2108374688 @default.
• W3043131535 cites W2163709153 @default.
• W3043131535 cites W2999417355 @default.
• W3043131535 cites W3006355661 @default.
• W3043131535 cites W3008028633 @default.
• W3043131535 cites W3008827533 @default.
• W3043131535 cites W3012655533 @default.
• W3043131535 cites W3016535995 @default.
• W3043131535 cites W3016785135 @default.
• W3043131535 cites W3016852213 @default.
• W3043131535 cites W3018805214 @default.
• W3043131535 cites W3019820338 @default.
• W3043131535 cites W3021540821 @default.
• W3043131535 cites W3021821162 @default.
• W3043131535 cites W3021954309 @default.
• W3043131535 cites W3022415528 @default.
• W3043131535 cites W3023300354 @default.
• W3043131535 cites W3026217487 @default.
• W3043131535 cites W3026764413 @default.
• W3043131535 cites W3028583791 @default.
• W3043131535 cites W3028965239 @default.
• W3043131535 cites W3030573714 @default.
• W3043131535 cites W3034129242 @default.
• W3043131535 cites W3037848912 @default.
• W3043131535 cites W966445620 @default.
• W3043131535 doi "https://doi.org/10.1182/blood.2020006965" @default.
• W3043131535 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7472711" @default.
• W3043131535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32688395" @default.
• W3043131535 hasPublicationYear "2020" @default.
• W3043131535 type Work @default.
• W3043131535 sameAs 3043131535 @default.

• next